These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16247429)

  • 1. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.
    Shapira MY; Resnick IB; Bitan M; Ackerstein A; Tsirigotis P; Gesundheit B; Zilberman I; Miron S; Leubovic A; Slavin S; Or R
    Bone Marrow Transplant; 2005 Dec; 36(12):1097-101. PubMed ID: 16247429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus.
    Shapira MY; Resnick IB; Dray L; Aker M; Stepensky P; Elad S; Gesundeheidt B; Samuel S; Or R
    Cytotherapy; 2009; 11(1):61-7. PubMed ID: 19191054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alefacept treatment for refractory chronic extensive GVHD.
    Shapira MY; Abdul-Hai A; Resnick IB; Bitan M; Tsirigotis P; Aker M; Gesundheit B; Slavin S; Or R
    Bone Marrow Transplant; 2009 Feb; 43(4):339-43. PubMed ID: 18850020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
    Toor AA; Stiff PJ; Nickoloff BJ; Rodriguez T; Klein JL; Gordon KB
    J Dermatolog Treat; 2007; 18(1):13-8. PubMed ID: 17365261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
    Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
    Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
    Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
    Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.
    Perfetti P; Carlier P; Strada P; Gualandi F; Occhini D; Van Lint MT; Ibatici A; Lamparelli T; Bruno B; Raiola AM; Dominietto A; Di Grazia C; Bregante S; Zia S; Ferrari GM; Stura P; Pogliani E; Bacigalupo A
    Bone Marrow Transplant; 2008 Nov; 42(9):609-17. PubMed ID: 18660840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
    Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
    Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
    Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
    Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
    Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.